CD69 is a type II C-lectin transmembrane receptor that serves as a classical early activation marker appearing within one hour of T cell receptor stimulation 1. Beyond its role as an activation marker, CD69 functions as a critical regulator of tissue residency and immune cell homeostasis. It is constitutively expressed on tissue-resident memory T cells (TRMs) in diverse mucosal and lymphoid tissues, where it defines a core transcriptional signature distinct from circulating memory T cells 2. CD69 mechanistically regulates lymphocyte migration by acting as an S1PR1 receptor agonist, facilitating receptor internalization and degradation, thereby preventing tissue egress in response to sphingosine-1-phosphate 3. The molecule plays opposing roles in different immune contexts: it negatively regulates Th17 differentiation through galectin-1 interactions and promotes regulatory T cell conversion 4. In cancer immunotherapy, CD69 expression patterns distinguish functional T cell subsets, with CD39-CD69- stem-like T cells associated with superior therapeutic responses compared to terminally differentiated CD39+CD69+ cells 5. Additionally, CD69 contributes to inflammatory pathology through interactions with myosin light chains in airway inflammation 6 and by inducing vascular leak through S1PR1 downregulation in activated endothelial cells 7.